专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

US09872879B2 Process for the preparation of plant extracts for treating skin disorders and enhancing healing of wounds 有权
公开(公告)号：US09872879B2
公开(公告)日：2018-01-23
申请号：US13872723
申请日：2013-04-29
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY
发明人： Rey-Yuh Wu , Yuh-Shan Chung , Yu-Yuan Wu , Ma-Li Siu , Chin-Wen Hsiao
IPC分类号： A61K36/53 , A61K36/23
CPC分类号： A61K36/53 , A61K36/23
摘要： The present invention provides a process for the preparation of Plectranthus amboinicus extracts using a stirring separation method. The present invention also relates to a pharmaceutical composition comprising the Plectranthus amboinicus crude extract and/or extract for treating skin disorders, including enhancing the healing of wounds, especially in diabetic patients.

72. 发明授权

US09527922B2 Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy 有权
标题翻译：人源化α-烯醇酶特异性抗体及其在癌症治疗中的应用方法
公开(公告)号：US09527922B2
公开(公告)日：2016-12-27
申请号：US14588212
申请日：2014-12-31
申请人： Development Center for Biotechnology , DCB-USA LLC , National Health Research Institutes
发明人： Shih-Chong Tsai , Ta-Tung Yuan , Shih-Chi Tseng , Jiann-Shiun Lai , Chia-Cheng Wu , Chao-Yang Huang , Ya-Wei Tsai , Ying-Yung Lok , Chung-Hsiun Wu , Neng-Yao Shih , Ko-Jiunn Liu , Li-Tzong Chen
IPC分类号： A61K39/395 , C07K16/40 , A61K39/00
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.
摘要翻译：人源化抗体或其结合片段，其中所述人源化抗体结合人ENO1（GenBank：AAH50642.1），其中所述抗体包含轻链可变区（VL）结构域，其包含具有氨基酸序列LCDR1（RASENIYSYLT; SEQ ID NO：6）和具有氨基酸序列LCDR2（NAKTLPE; SEQ ID NO：7）的CDR2和具有氨基酸序列LCDR3（QHHYGTPYT; SEQ ID NO：8）和抗体重链可变区（ VH）结构域，其包含具有氨基酸序列HCDR1（GYTFTSCVMN; SEQ ID NO：3）的CDR1，具有氨基酸序列HCDR2（YINPYNDGTKYNEKFKG; SEQ ID NO：4）的CDR2和具有氨基酸序列HCDR3（EGFYYGNFDN ; SEQ ID NO：5），其中轻链可变区（VL）结构域和重链可变区（VH）结构域中的构架区包含来自人免疫球蛋白的氨基酸序列。

73. 发明授权

US09447193B2 Methods for suppressing cancer by inhibition of TMCC3 有权
标题翻译：抑制TMCC3抑制癌症的方法
公开(公告)号：US09447193B2
公开(公告)日：2016-09-20
申请号：US14223800
申请日：2014-03-24
申请人： Development Center for Biotechnology , Academia Sinica , Chang Gung Memorial Hospital
发明人： Alice L. Yu , John Yu , Ya-Hui Wang , Chuan-Lung Hsu , Yi-Chang Chen , Ying-Yung Lok
IPC分类号： A61K39/395 , C07K16/30 , G01N33/574 , C12Q1/68
CPC分类号： C07K16/3015 , A61K39/39558 , C07K16/30 , C07K2317/55 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C12Q1/6886 , C12Q2600/158 , G01N33/57496
摘要： A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.
摘要翻译：治疗癌症的方法包括向有需要的受试者施用针对跨膜和卷曲螺旋结构域蛋白3（TMCC3）的抗体，其中所述抗体结合TMCC3的细胞外结构域中的表位。抗体结合TMCC3的线粒体结构域中的表位。一种诊断或评估癌症病症的方法包括评估样品中跨膜和卷曲螺旋结构域蛋白3（TMCC3）的表达或活性水平，其中TMCC3的活性表达水平与标准表明样品中存在癌干细胞。

74. 发明授权

US09150482B2 GLP-1 potentiators from hedychium coronarium and their applications 有权
标题翻译：来自hedychium coronarium的GLP-1增效剂及其应用
公开(公告)号：US09150482B2
公开(公告)日：2015-10-06
申请号：US13912102
申请日：2013-06-06
申请人： Rey-Yuh Wu , Hui-Ling Chen , Yu-Yuan Wu , Jiann-Jyh Huang , Shoei-Sheng Lee , K-Lim King
发明人： Rey-Yuh Wu , Hui-Ling Chen , Yu-Yuan Wu , Jiann-Jyh Huang , Shoei-Sheng Lee , K-Lim King
IPC分类号： A61K38/26 , A61K31/397 , A61K31/335 , C07C321/00 , C07C45/00 , C07C47/225 , C07D309/30 , C07D321/04 , C07C47/267 , C07D205/12 , C07D305/14 , A61K31/11 , A61K31/351 , A61K31/357 , C07C47/46 , A61K36/9068 , A61K45/06 , A61K31/365 , C07C47/277 , A61K31/337
CPC分类号： C07C47/225 , A61K31/11 , A61K31/337 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/397 , A61K36/9068 , A61K38/26 , A61K45/06 , C07C47/267 , C07C47/277 , C07C47/46 , C07C2602/26 , C07C2603/30 , C07D205/12 , C07D305/14 , C07D309/30 , C07D321/04 , A61K2300/00
摘要： A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a subject in need thereof a compound of Formula I. The method further includes administering to the subject a GLP-1 receptor ligand. The compound and the GLP-1 receptor ligand may be administered together. The compound may be Galanal A or Galanal B. The GLP-1 receptor ligand may be GLP-1 or exendin-4.
摘要翻译：用于控制血糖水平的化合物具有式I所示的结构：其中R5-R8如本文所定义。用于控制血糖水平的方法包括向有需要的受试者施用式I的化合物。该方法还包括向受试者施用GLP-1受体配体。化合物和GLP-1受体配体可以一起施用。该化合物可以是Galanal A或Galanal B. GLP-1受体配体可以是GLP-1或毒蜥外泌肽-4。

75. 发明申请

US20150182572A1 PLANT EXTRACT AND THE PROCESS FOR TREATING HEPATIC FIBROSIS AND LIVER CANCER 有权
标题翻译：植物提取物和治疗肝硬化和肝癌的方法
公开(公告)号：US20150182572A1
公开(公告)日：2015-07-02
申请号：US14144264
申请日：2013-12-30
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY
发明人： Yuh-Shan Chung , Ma-Li Siu , Tzung-Hsien Lai , Szu-Chien Yeh
IPC分类号： A61K36/41
CPC分类号： A61K36/41 , A61K2236/00
摘要： An extract of Graptopetalum paraguayense prepared by a method that includes: extracting a Graptopetalum paraguayense (GP) starting material with an alcoholic solvent to produce an alcoholic extract and a residue; separating the residue from the alcoholic extract; extracting the residue with an aqueous dimethyl sulfoxide (DMSO) solvent to produce a DMSO extract; subjecting the DMSO extract to ultrafiltration using a filter having a selected molecular weight cutoff; drying a fraction retained by the filter to obtain the extract of Graptopetalum paraguayense. Uses of an extract of Graptopetalum paraguayense for the treatment or prevention of liver fibrosis, hepatic cirrhosis, liver cancer, recurrence of liver fibrosis after surgery, or recurrence of liver cancer after surgery.
摘要翻译：通过包括以下方法制备的Graptopetalum巴拉圭的提取物包括：用醇溶剂萃取Graptopetalum巴拉圭（GP）起始原料以产生醇提取物和残余物; 从酒精提取物中分离残留物; 用二甲基亚砜（DMSO）水溶液萃取残余物，得到DMSO提取物; 使用具有选择的分子量截止值的过滤器对DMSO提取物进行超滤; 干燥由过滤器保留的部分，以获得格拉菲叶醋巴拉圭的提取物。 Graptopetalum paraguayense的提取物用于治疗或预防肝纤维化，肝硬化，肝癌，手术后肝纤维化复发或手术后肝癌复发。

76. 发明申请

US20130274255A1 HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF 有权
标题翻译：杂环吡唑化合物，其制备方法和用途
公开(公告)号：US20130274255A1
公开(公告)日：2013-10-17
申请号：US13445161
申请日：2012-04-12
申请人： Chu-Bin LIAO , Chao-Cheng CHIANG , Huei-Ru YANG , Yuan-Chun LIAO , Paonien CHEN
发明人： Chu-Bin LIAO , Chao-Cheng CHIANG , Huei-Ru YANG , Yuan-Chun LIAO , Paonien CHEN
IPC分类号： A61K31/4162 , A61K31/4439 , A61K31/454 , A61K31/506 , A61P37/06 , A61K31/5377 , A61P35/00 , A61P37/00 , A61P37/08 , C07D495/04 , A61K31/496
CPC分类号： C07D495/04
摘要： The present invention relates to a compound of formula (I): or hydrates, solvates, prodrugs, or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, ring A, R3 and R4 are as defined in the detailed description and claims.The compound of formula (I) are receptor tyrosine kinase (RTK) inhibitors and have efficacy for the treatment, prevention, or amelioration of RTK-related diseases.
摘要翻译：本发明涉及式（I）的化合物或其水合物，溶剂合物，前药或其药学上可接受的盐，其中R 1，R 2，X，Y，环A，R 3和R 4如在详细描述和权利要求书中所定义。式（I）化合物是受体酪氨酸激酶（RTK）抑制剂，具有治疗，预防或改善RTK相关疾病的功效。

77. 发明授权

US08088394B2 Mutated E. coli heat-labile enterotoxin 有权
标题翻译：突变大肠杆菌热不稳定肠毒素
公开(公告)号：US08088394B2
公开(公告)日：2012-01-03
申请号：US12120953
申请日：2008-05-15
申请人： Yu-Shen Hsu , Young-Sun Lin , Ta-Tung Yuan
发明人： Yu-Shen Hsu , Young-Sun Lin , Ta-Tung Yuan
IPC分类号： A61K39/00 , A61K39/02 , A61K39/108 , C07H21/02 , C07H21/04 , C12N15/00
CPC分类号： A61K39/39 , A61K39/12 , A61K39/145 , A61K2039/5252 , A61K2039/543 , A61K2039/55544 , C07K14/245 , C12N2760/16134
摘要： This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity compared to its wild type counterpart.
摘要翻译：本发明涉及可用作佐剂的突变大肠杆菌热不稳定肠毒素（LT）亚基A。该亚基A突变体在对应于野生型LT的位置61的位置处含有氨基酸取代。含有该突变亚基A的LT与其野生型对应物相比毒性降低。

78. 发明申请

US20100152226A1 SUSTAINED RELEASE IMPLANT FOR GRANISETRON 有权
标题翻译：可持续发展的Granan植物
公开(公告)号：US20100152226A1
公开(公告)日：2010-06-17
申请号：US12426721
申请日：2009-04-20
申请人： Paonien Chan , Shou-Chung Chao , Shu-Chien Liu , Fan-Jung Liu , Li-Ya Wang
发明人： Paonien Chan , Shou-Chung Chao , Shu-Chien Liu , Fan-Jung Liu , Li-Ya Wang
IPC分类号： A61K31/439
CPC分类号： A61K31/439 , A61K9/0024
摘要： The main goals of the invention are to develop the long-term release of Granisetron injection implant composition with biodegradable polymer and to develop relative processing. Granisetron is mixed with different biodegradable polymers, and then hot melt extrusion technique with different diameter, temperature, rate of extrusion and holding time is applied to make implant. In vitro dissolution of the Granisetron injection implant composition shows the component continued release of the drug for over 7 days.
摘要翻译：本发明的主要目标是开发具有可生物降解聚合物的格拉司琼注射剂组合物的长期释放并开发相对加工。格拉司琼与不同的可生物降解聚合物混合，然后应用不同直径，温度，挤出速率和保持时间的热熔挤出技术来制造植入物。格拉司琼注射剂组合物的体外溶出显示药物持续释放7天以上。

79. 发明授权

US07531194B2 Plant extracts for the treatment of rheumatoid arthritis 有权
标题翻译：用于治疗类风湿关节炎的植物提取物
公开(公告)号：US07531194B2
公开(公告)日：2009-05-12
申请号：US11893207
申请日：2007-08-15
申请人： Rey-Yuh Wu , Jia-Ming Chang , Chun-Ming Cheng , Yuh-Shan Chung
发明人： Rey-Yuh Wu , Jia-Ming Chang , Chun-Ming Cheng , Yuh-Shan Chung
IPC分类号： A01N65/10
CPC分类号： A61K36/53
摘要： A pharmaceutical composition comprising a crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng (PA) for the treatment of rheumatoid arthritis is described. The use of the crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng for the manufacture of medicaments for treating rheumatoid arthritis is also described.
摘要翻译：描述了包含用于治疗类风湿性关节炎的Plectranthus Amboinicus（Lour。）Spreng（PA）的粗提取物或提取物的药物组合物。还描述了用于制备用于治疗类风湿性关节炎的药物的粗提取物或茯苓提取物（Lour。）Spreng的用途。

80. 发明授权

US07153933B2 Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same 有权
公开(公告)号：US07153933B2
公开(公告)日：2006-12-26
申请号：US10308644
申请日：2002-12-03
申请人： Shih-Kwang Wu , Ting-Gung Chang , Chin-Lu Tseng , Li-Jung Chen , Kae-Shyang Shih
发明人： Shih-Kwang Wu , Ting-Gung Chang , Chin-Lu Tseng , Li-Jung Chen , Kae-Shyang Shih
IPC分类号： C07K1/04 , C07K2/00 , C07K1/00 , C07K7/64
CPC分类号： A61K9/1271 , A61K38/00 , C07K1/04 , C07K1/1077 , C07K14/4753 , C07K14/48 , C07K14/485 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/52 , C07K14/57563 , C07K14/65 , C07K14/655 , C07K14/75 , C07K14/78 , Y02P20/55
摘要： A solid phase synthesis method for preparing peptide-spacer-lipid conjugates, the peptide-spacer-lipid conjugates synthesized by the method, and liposomes containing the peptide-spacer-lipid conjugates. The present invention provides a convenient solid phase synthesis method for preparing peptide-spacer-lipid conjugates and provides various linkage groups (such as amide group) for conjugating peptide, spacer and lipid, wherein the spacer may comprise PEG. Several advantages can be achieved, such as the synthetic procedure can be simplified, the synthesis process can be set to automation, the purification is easier in each reaction step, and the product losses can be reduced to minimal during synthesis. The present synthesis method is suitable for preparing a wide range of peptide-spacer-lipid conjugates, provides a peptide-spacer-lipid conjugate prepared by the solid phase synthesis method of the present invention, which can be incorporated into a liposome as the targeting moiety for liposomal drug delivery to specific cells, and provides a targeting liposome containing the present peptide-spacer-lipid conjugate.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式